Takeda Pharmaceutical Co Ltd (TAK)
Takeda makes and sells branded prescription medicines, selling to hospitals, insurers and government health programs in Japan, the U.S. and Europe. It last closed at $20.88 on Nov 2, down 0.19% on the day. TAK reports earnings on Thu, Jan 28, 2027.
Key Stats
Fiscal 2025Not reported for this period.
From TAK's SEC filings, latest 20-F for the period ending Mar 31, 2025 (filed Jun 17). Figures are in JPY. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Earnings calendar →Technical Analysis
The stock is 6% above its 20 day and 10% above its 50 day average. It is 16% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 71), overbought. The nearest support is the Pivot S1 at $20.72, and the nearest resistance the Pivot at $20.94.
| RSI (14) | 71.23 | Overbought above 70 | Overbought |
| MACD | 0.57 | Above its signal line | Bullish |
| Stochastic | 83.0 | Near the top of its range | Overbought |
| ADX (14) | 33.8 | Trending up | |
| Williams %R | -12.8 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 121.6 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +6.5% | Change over 10 sessions | Bullish |
| ATR (14) | $0.43 | Typical daily range, 2.1% of price |
| RSI (14) | 72.61 | Overbought above 70 | Overbought |
| MACD | 0.95 | Above its signal line | Bullish |
| Stochastic | 94.4 | Near the top of its range | Overbought |
| ADX (14) | 21.5 | Weak trend | |
| Williams %R | -6.9 | Oversold below −80, overbought above −20 | Overbought |
| CCI (20) | 177.9 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +15.8% | Change over 10 sessions | Bullish |
| ATR (14) | $0.85 | Typical daily range, 4.1% of price |
What happened before
See how TAK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How TAK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2008.
Whale Options Flow
90DNo whale options trades in TAK in the last 90 days.
TAK Institutional Ownership
Hedge fund holdings →- Fmr LLC+2.5M sh$39.8M
- Qube Research & Technologies Ltd+2.2M sh$35.4M
- Millennium Management LLC+1.1M sh$16.8M
- AQR Capital Management LLC+631K sh$10.1M
- Arrowstreet Capital, Limited Partnership+617K sh$9.9M
- Morgan Stanley+525K sh$8.4M
- UBS Group AG−1.8M sh−$29.3M
- Capital Wealth Planning, LLC−887K sh−$16.4M
- Van Eck Associates Corp−586K sh−$9.4M
- D. E. Shaw & Co., Inc.−553K sh−$8.9M
- Goldman Sachs Group Inc−494K sh−$7.9M
- Citadel Advisors LLC−456K sh−$7.3M
- Abc Arbitrage SANew+564K shOct 23
- Creative PlanningAdded+124K shNov 2
- Vise Technologies, Inc.Added+62K shOct 29
- Quadrant Capital Group LLCAdded+55K shOct 20
- Assetmark, IncTrimmed−26K shOct 21
- Burns Matteson Capital Management, LLCSold out−26K shOct 16
- Crossmark Global Holdings, Inc.Trimmed−22K shOct 21
- Inscription Capital, LLCSold out−21K shNov 2
From SEC Form 13F filings by funds managing over $100 million, as of Jun 30, 2026. Changes compare each fund with its own Q1 2026 filing. Filings come up to 45 days after the quarter ends. Put/call compares the value of puts and calls funds reported ($492K in puts, $1.6M in calls), leaving out market makers and bank trading desks. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether TAK is in one of them and how their past TAK trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered TAK in an article yet. Here's the latest on the wider market.
TAK Congress Trades
All congress trades →
| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Alan ArmstrongHouse | Buy | $1K – $15K | Mar 30, 2026 | Jul 21, 2026 | 113 d |
| Ro KhannaD · CA | Sell | $1K – $15K | May 9, 2025 | Jun 12, 2025 | 34 d |
| Ro KhannaD · CA | Buy | $1K – $15K | Mar 14, 2025 | Apr 11, 2025 | 28 d |
| Virginia FoxxR · NC | Sell | $15K – $50K | Aug 29, 2023 | Sep 5, 2023 | 7 d |
| Dan GoldmanD · NY | Sell | $15K – $50K | Jul 10, 2023 | Aug 13, 2023 | 34 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Takeda Pharmaceutical Co
Takeda is a pharmaceutical company based in Tokyo, Japan, that makes and sells branded prescription medicines. Its products are sold in the United States, Europe, Japan and emerging markets such as China. Its customers include hospitals and medical institutions, insurers and managed care groups, pharmacy benefit managers, and government health programs. Its products face price pressure and competition from generic and biosimilar versions once patent or regulatory protection ends.
- Headquarters
- Tokyo, Japan